No products in the cart
Semax peptides are Synthesized and Lyophilized in the USA.
Discount per Quantity
|Quantity||5 - 9||10 +|
FREE - 30ml bottle of bacteriostatic water
(Required for reconstitution)
FREE - USPS priority shipping
What is the Semax peptide?
Semax is a synthetic analog of adrenocorticotropic hormone (ACTH) comprising amino acids 4-10 of ACTH. Semax has been researched for its potential to benefit strokes, cognitive impairment, dementia, and inflammations of the optic nerve. It appears to boost the immune system, act as an antidepressant, and possess anxiolytic properties. Semax has been observed by reseachers to increase the production of brain-derived neurotrophic factor (BDNF) in the central nervous system and serotonin and dopamine levels.
Molecular Formula: C37H51N9O10S
Molecular Weight: 813.920 g/mol
PubChem: CID 122178
CAS Number: 4037-01-8
Semax and Strokes
In Russia, Semax is used to treat acute cerebral hypoxia caused by stroke or traumatic brain injury. As per studies in rats, Semax appears to promote the expression of 24 genes in the brain and spinal cord through various molecular mechanisms. These genes modulate various functions from smooth muscle cell migration to red blood cell formation and angiogenesis. The peptide has been suggested to promote the survival of neurons, stabilize mitochondria, increase energy production, and enhance the supply of nutrition to the brain. The scientists report that “The immunomodulating effect of the peptide discovered in our research and its impact on the vascular system during ischemia are likely to be the key mechanisms underlying the neuroprotective effects of the peptide.” As per studies in Russia, Semax may accelerate the rate of rehabilitation in stroke patients and results in a greater overall level of function upon completing the treatment. Gusev et al. observe, “early rehabilitation and administration of Semax increase BDNF plasma levels, speed functional recovery, and improve motor performance.” BDNF is a natural brain peptide that promotes learning and memory. BDNF stimulation enhances neuroplasticity in the brain and helps undamaged regions of the brain learn tasks for which damaged regions were responsible. Semax is suggested to activate the default mode network, which is crucial for resting attention and social function.
Semax and Resting Brain Structure
Semax has been observed through functional magnetic resonance imaging to trigger the function of what is known as the default mode network. The default mode network includes areas of the brain which remain more active during rest than during any activity. Recent studies report this brain region to be engaged in social cognition and monitoring of the environment. It is a general-purpose system for observing the world around us, without focusing on specific elements. The network is an important part of attention as it helps individuals change from a “rest” state to a more attentive form. In diseases compromising cognitive power like Alzheimer’s, the default mode network is often affected, proving its involvement in general social awareness. Researchers suggest Semax may boost default network activity and improve our general level of awareness, even during rest. This brings about greater attention and focus and being attentive to the social environment. Thus it helps the brain readily switch from a resting state to a focused state. Increased activity in the default mode network corresponds to improved neural connections within the brain. These connections lead to better problem solving, enhanced memory, and creativity. The peptide is thought to boost global brain function through this domino chain of cognitive functioning.
Semax and Gene Expression in the Brain
Semax appears to mediate changes in gene expression in the brain and may not pertain to stroke only. Studies report administration of the peptide may trigger differential gene regulation in rats’ frontal cortex and hippocampus. This is relevant as the hippocampus regulates memory and learning, whereas the frontal cortex helps concentrate, plan, and organize information. In both regions of the brain, scientists observed that gene expression spikes within 20 minutes of Semax administration and specifically appeared to influence nerve growth factor (NGF) and BDNF. The researchers concluded that “Semax administration results in rapid, long-term, and specific activation of Bdnf and Ngf expression changes in different rat brain departments.” Therefore, the peptide may help study the mechanisms of learning and information processing. It may further assist in exploring cognition and easier and permanent learning.
Semax and Cognitive Performance
Semax studies suggest its administration may be an effective way for learning and memory enhancement, especially when these functions get neurologically impaired. ACTH, the natural protein source of Semax, appears to preserve memory function and learning in murine models of epilepsy, as shown in studies from Canada, China, and the United States. It has been studied for its potential in treating epileptic disorder. According to Dr. Scantlebury, Semax is a potentially potent derivative of ACTH and may provide benefits absent in the natural peptide. Preliminary reports sugagest that even low doses of ACTH help prevent learning and memory dysfunction following a seizure. This indicates ACTH and Semax may possess nootropic properties and may also promote cognitive performance when used regularly in minimal doses.
Semax and Depression
Murine studies have observed that elevated BDNF may influence the function of the brain in the setting of depression. Current antidepressants, like SSRIs, indirectly regulate serotonin signaling in the brain to alleviate the condition, but prolonged treatment is required for any visible effect. Neurobiologists have thus always wanted a more immediate solution. It is now known that SSRIs take a prolonged duration due to their slow ability to increase BDNF in the depressed brain. According to Deltheil et al., a combination of Semax and SSRI could majorly improve the treatment of depression through prompt induction of BDNF. Experimental studies report Semax appears to exhibit minimal side effects, low oral bioavailability, and excellent subcutaneous bioavailability in mice. Per kg dosage in mice does not scale to humans.
- Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15:228. Published 2014 Mar 24. doi:10.1186/1471-2164-15-228.
- Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN. Éffektivnost’ semaksa pri lechenii bol’nykh na raznykh stadiiakh ishemicheskogo insul’ta [The efficacy of semax in the tretament of patients at different stages of ischemic stroke]. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3. Vyp. 2):61-68. doi:10.17116/jnevro20181183261-68.
- Lebedeva IS, Panikratova YR, Sokolov OY, et al. Effects of Semax on the Default Mode Network of the Brain. Bull Exp Biol Med. 2018;165(5):653-656. doi:10.1007/s10517-018-4234-3.
- Mars RB, Neubert FX, Noonan MP, Sallet J, Toni I, Rushworth MF. On the relationship between the “default mode network” and the “social brain”. Front Hum Neurosci. 2012;6:189. Published 2012 Jun 21. doi:10.3389/fnhum.2012.00189.
- Agapova TIu, Agniullin IaV, Silachev DN, et al. Mol Gen Mikrobiol Virusol. 2008;(3):28-32.
- Scantlebury MH, Chun KC, Ma SC, Rho JM, Kim DY. Adrenocorticotropic hormone protects learning and memory function in epileptic Kcna1-null mice. Neurosci Lett. 2017;645:14-18. doi:10.1016/j.neulet.2017.02.069
- Deltheil T, Guiard BP, Cerdan J, et al. Behavioral and serotonergic consequences of decreasing or increasing hippocampus brain-derived neurotrophic factor protein levels in mice. Neuropharmacology. 2008;55(6):1006-1014. doi:10.1016/j.neuropharm.2008.08.001
Dr. Usman (BSc, MBBS, MaRCP) completed his studies in medicine at the Royal College of Physicians, London. He is an avid researcher with more than 30 publications in internationally recognized peer-reviewed journals. Dr. Usman has worked as a researcher and a medical consultant for reputable pharmaceutical companies such as Johnson & Johnson and Sanofi.